key: cord-0781092-h94110vm
authors: Woods, J. Andrew
title: Evidence-based treatment during the SARS-CoV-2 pandemic: Identifying the knowns and unknowns of nebulization
date: 2020-09-30
journal: J Am Pharm Assoc (2003)
DOI: 10.1016/j.japh.2020.09.014
sha: 3d59dbbc9d3bdacf8083a3451430fc466a583400
doc_id: 781092
cord_uid: h94110vm

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus 19 (COVID-19), has resulted in a worldwide pandemic and currently represents a major public health issue. Among these considerations is the optimal delivery of inhaled bronchodilators to maximize patient care. Despite the lack of evidence, there is heightened concern about the potential risk for transmission of SARS-CoV-2 in the form of aerosolized respiratory droplets during the nebulized treatment of patients with COVID-19. In this commentary, the lack of evidence regarding nebulization and transmission of coronaviruses are discussed.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus 19 27 , has resulted in a worldwide pandemic and currently represents a major public 28 health issue. Among these considerations is the optimal delivery of inhaled bronchodilators to 29 maximize patient care. Despite the lack of evidence, there is heightened concern about the 30 potential risk for transmission of SARS-CoV-2 in the form of aerosolized respiratory droplets 31 during the nebulized treatment of patients with COVID-19. In this commentary, the lack of 32 evidence regarding nebulization and transmission of coronaviruses are discussed. 39 What this study adds: The potential risk of SARS-CoV-2 transmission through aerosolized respiratory droplets during 56 nebulized treatment of patients with COVID-19 is a currently unsubstantiated concern that has 57 served as the primary driver of a steep increase in the dispensing of albuterol metered-dose 

American College of Allergy Asthma and Immunology. A message to asthma sufferers